IP Library Granted Patent US 8,541,223
Granted Patent B2
US 8,541,223 · App. 13/544,756 · Granted Sep 24, 2013

Lactic acid bacteria having action of lowering blood uric acid level

Inventors: Hiroshi Tsuboi (Kanagawa, JP); Noriko Kaneko (Kanagawa, JP); Akina Satou (Kanagawa, JP); Yoshinobu Tsuchiya (Kanagawa, JP)
Assignee: Meiji Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,541,223
App. No.
13/544,756
Granted
Sep 24, 2013
Kind
B2
Abstract

Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found.

Claims (9)

1. A lactic acid bacterium Lactobacillus oris strain OLL2779 deposited as Accession No.: NITE BP-223, wherein the lactic acid bacterium is a biologically pure culture thereof.

2. A dietary product for suppressing an increase in blood uric acid level, comprising the lactic acid bacterium of claim 1 and/or a substance containing said lactic acid bacterium.

3. A pharmaceutical for suppressing an increase in blood uric acid level, comprising the lactic acid bacterium of claim 1 and/or a substance containing said lactic acid bacterium.

4. A pharmaceutical for treating hyperuricemia, comprising the lactic acid bacterium of claim 1 and/or a substance containing said lactic acid bacterium.

5. A dietary product for treating hyperuricemia, comprising the lactic acid bacterium of claim 1 and/or a substance containing said lactic acid bacterium.

6. A method for suppressing the level of purine ingested from food, wherein the method comprises administering the lactic acid bacterium of claim 1 and/or a substance containing said lactic acid bacterium.

7. A method for suppressing an increase in blood uric acid level, wherein the method comprises administering the lactic acid bacterium of claim 1 and/or a substance containing said lactic acid bacterium.

8. A method for producing a dietary product with reduced purine level, wherein the method comprises the step of contacting a raw material or intermediate product of the dietary product with the lactic acid bacterium of claim 1 and/or a substance containing said lactic acid bacterium.

9. A method for treating any one or more diseases or symptoms from the group consisting of hyperuricemia, gout, renal dysfunction, urinary stone, and arteriosclerosis, wherein the method comprises administering the lactic acid bacterium of claim 1 and/or a substance containing said lactic acid bacterium.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2012
From: TSUBOI, HIROSHI; KANEKO, NORIKO; SATOU, AKINA; TSUCHIYA, YOSHINOBU
To: MEIJI DAIRIES CORPORATION
Reel/Frame 029368/0346 →
CHANGE OF NAME Recorded Nov 28, 2012
From: MEIJI DAIRIES CORPORATION
To: MEIJI CO., LTD.
Reel/Frame 029374/0090 →
Continuity (2)
Division 12745007
Related Publication 20120308539A1 · Dec 6, 2012